Stay updated on Tuspetinib in AML: Safety & Efficacy Clinical Trial
Sign up to get notified when there's something new on the Tuspetinib in AML: Safety & Efficacy Clinical Trial page.

Latest updates to the Tuspetinib in AML: Safety & Efficacy Clinical Trial page
- Check4 days agoChange DetectedNo substantive changes detected between the old and new screenshots of the ClinicalTrials.gov study page; content and structure appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check33 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference2%

- Check40 days agoChange DetectedNew contact details and an updated revision version (v3.1.0) were added, replacing the previous v3.0.2.SummaryDifference0.0%

- Check55 days agoChange DetectedUpdate to v3.0.2 from v3.0.1 and removal of the Back to Top link; a small release update with a minor navigation change.SummaryDifference0.1%

- Check62 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

- Check69 days agoChange DetectedThe web page has been updated to include new facility names, locations, and a clinical trial for Tuspetinib in patients with relapsed or refractory acute myeloid leukemia, while also removing outdated information about previous trials and locations.SummaryDifference10%

Stay in the know with updates to Tuspetinib in AML: Safety & Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tuspetinib in AML: Safety & Efficacy Clinical Trial page.